和元生物
(688238)
| 流通市值：33.33亿 | | | 总市值：46.23亿 |
| 流通股本：4.67亿 | | | 总股本：6.47亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 59,574,128.09 | 204,805,008.26 | 136,994,292.35 | 83,750,990.53 |
| 营业收入 | 59,574,128.09 | 204,805,008.26 | 136,994,292.35 | 83,750,990.53 |
| 二、营业总成本 | 117,835,749.83 | 360,583,467.55 | 229,680,716.89 | 141,854,905.03 |
| 营业成本 | 71,976,427.14 | 218,223,594.88 | 129,924,115.82 | 82,171,415.71 |
| 税金及附加 | 1,161,320.01 | 2,124,048.18 | 787,746.62 | 545,858.78 |
| 销售费用 | 11,504,200.06 | 41,968,797.79 | 28,394,127.8 | 17,526,177.95 |
| 管理费用 | 19,964,548.56 | 63,548,680.82 | 44,448,917.9 | 26,660,012.38 |
| 研发费用 | 13,787,220.55 | 50,916,965.6 | 38,580,900.32 | 24,338,797.45 |
| 财务费用 | -557,966.49 | -16,198,619.72 | -12,455,091.56 | -9,387,357.24 |
| 其中:利息费用 | 1,781,031.96 | 6,829,497.86 | 5,034,157.4 | 3,193,176.76 |
| 其中:利息收入 | 2,343,929.06 | 23,112,140.3 | 17,560,612.41 | 12,653,683.41 |
| 加:公允价值变动收益 | 61,000 | 12,657.53 | 12,657.53 | 12,657.53 |
| 加:投资收益 | -460,954.89 | -1,169,202.25 | -846,664.36 | -494,272.96 |
| 资产处置收益 | -14,606.88 | 101,679.09 | 145,390.55 | -376.85 |
| 资产减值损失(新) | -559,134.22 | -13,299,401.55 | -289,418.84 | 38,759.75 |
| 信用减值损失(新) | 1,152,508.31 | -1,064,213.84 | -1,702,279.38 | -1,328,628.39 |
| 其他收益 | 7,147,841.94 | 15,750,926.82 | 7,687,104.27 | 4,842,943.69 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -50,934,967.48 | -155,446,013.49 | -87,679,634.77 | -55,032,831.73 |
| 加:营业外收入 | 23,967.35 | 99,419.9 | 32,417.74 | 11,797.25 |
| 减:营业外支出 | 5,764.52 | 257,015.42 | 1,765.34 | 1,765.34 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -50,916,764.65 | -155,603,609.01 | -87,648,982.37 | -55,022,799.82 |
| 减:所得税费用 | -8,617,994.37 | -27,789,914.59 | -16,644,543.16 | -10,341,618.95 |
| 六、净利润 | -42,298,770.28 | -127,813,694.42 | -71,004,439.21 | -44,681,180.87 |
| 持续经营净利润 | -42,298,770.28 | -127,813,694.42 | -71,004,439.21 | -44,681,180.87 |
| 归属于母公司股东的净利润 | -42,170,292.32 | -127,938,329.85 | -71,099,570.54 | -44,797,891.77 |
| 少数股东损益 | -128,477.96 | 124,635.43 | 95,131.33 | 116,710.9 |
| (一)基本每股收益 | -0.07 | -0.2 | -0.11 | -0.07 |
| (二)稀释每股收益 | -0.07 | -0.2 | -0.11 | -0.07 |
| 八、其他综合收益 | -438,211.74 | 372,939.21 | 591,384.38 | 648,939.54 |
| 归属于母公司股东的其他综合收益 | -438,211.74 | 372,939.21 | 591,384.38 | 648,939.54 |
| 九、综合收益总额 | -42,736,982.02 | -127,440,755.21 | -70,413,054.83 | -44,032,241.33 |
| 归属于母公司股东的综合收益总额 | -42,608,504.06 | -127,565,390.64 | -70,508,186.16 | -44,148,952.23 |
| 归属于少数股东的综合收益总额 | -128,477.96 | 124,635.43 | 95,131.33 | 116,710.9 |
| 公告日期 | 2024-04-29 | 2024-04-25 | 2023-10-26 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |